Shots: The EC has approved Nyvepria, a biosimilar referencing Neulasta to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic CT for malignancy The EC approval is based data demonstrating a high degree of similarity of Nyvepria to its reference product Pfizer plans to make Nyvepria available […]Read More
The average life expectancy span of Human Beings are increased due to better medical facilities and drugs developed by Biopharma companies. Pharmaceutical products or drugs or medicines are being produced for a wide range of medical sectors. It includes the lifesaving drugs or the major therapy area including immunology, cardiology, and neurology but are they […]Read More
Shots: Pelmeg (Pegfilgrastim, Biosimilar) is indicated to reduce the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic CT for malignancy CHMP recommends Pelmeg based on the results from pharmacodynamics, pharmacokinetics, and immunogenicity comparisons with Neulasta Pelmeg is Granulocyte-colony stimulating factor (G-CSF) biosimilar that stimulates bone marrow to produce more […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
